PLUS THERAPEUTICS INC (PSTV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.10+2.65%
Close 2026-08-27 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PSTV
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Q2 2026 AND RECENT HIGHLIGHTS Corporate • Rebranded from Plus Therapeutics, Inc. to Cerenome, Inc., effective August 3, 2026, with the Company’s common stock trading on the Nasdaq Capital Market unde…
Stated in 2 of 2 supplied quarters. Management reported: “Q2 2026 AND RECENT HIGHLIGHTS Corporate • Rebranded from Plus Therapeutics, Inc. to Cerenome, Inc., effective August 3, 2026, with the Company’s common stock trading on the Nasdaq Capital Market under the ticker symbol “CNSY” REYOBIQ™ Development • Continued enrollment in the ReSPECT-LM multiple-dose clinical trial.” “As of June 30, 2026, approximately one-third of patients had been enrolled, with no dose-limiting toxicities observed to date, supporting the development of a recommended Phase 2 dose/dosing regimen by year-end • Continued enrollment in the ReSPECT-GBM Phase 2 trial.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Q2 2026 AND RECENT HIGHLIGHTS Corporate • Rebranded from Plus Therapeutics, Inc. to Cerenome, Inc., effective August 3, 2026, with the Company’s common stock trading on the Nasdaq Capital Market unde…”
“Concurrently, we secured FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas, while progressing on the ReSPECT-LM clinical trial.”
First dosing expected in the third quarter of 2026.
Stated in 2 of 2 supplied quarters. Management reported: “First dosing expected in the third quarter of 2026.” “First dosing expected in the third quarter of 2026.”
“First dosing expected in the third quarter of 2026.”
“"We continue to add payers for CNSide, including a fourth national payer, expanding coverage to approximately 81 million covered lives, as well as receiving a unique PLA code for billing and successf…”
"Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company," said Marc H.
Stated in 2 of 2 supplied quarters. Management reported: “"Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company," said Marc H.” “"Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company," said Marc H.”
“"Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company," said Marc H.”
“We enter the second quarter with the resources and focus to continue to deliver on our 2026 milestones."”
Develop and integrate CNSide diagnostics, REYOBIQ therapeutics, and AI-driven data analytics to improve CNS cancer patient outcomes.
Appoint senior executives to support clinical development, market access, and R&D execution for CNS oncology programs.
Over the trailing year it converted 0.60x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates, the US dollar (low R² over the window).
19 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-04.